People · Operator

Jude Paganelli

Named in public records as an officer, director or promoter · active 2016–2020 · Pharmaceuticals, Other

2
Companies
4
Filings
$127.8M
Combined raised · real
Serial
Operator type
Companies
CompanyRoleSectorStageRaised · realValue · estTied
Osteal Therapeutics, Inc.PharmaceuticalsSeries C$127.5M$87.1M2018
Delta Ortho, LLCOtherPre-Seed$240K$5.5M2016
Operator network

Jude Paganelli at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.

David Thompson · 10 companies · 1 sharedDavid ThompsonRenee Ryan · 6 companies · 1 sharedRenee RyanDouglas Kohrs · 4 companies · 1 sharedDouglas KohrsRushu Luo · 3 companies · 1 sharedRushu LuoBiren Mehta · 2 companies · 1 sharedBiren MehtaDavid Cash · 2 companies · 1 sharedDavid CashMartin Sands · 2 companies · 1 sharedMartin SandsNoam Krantz · 2 companies · 1 sharedNoam KrantzBrian De Beaubien · 1 companies · 1 sharedBrian De BeaubienErik Oros · 1 companies · 1 sharedErik OrosJudson Cooper · 1 companies · 1 sharedJudson CooperSonal Patel · 1 companies · 1 sharedSonal PatelBenjamin Arnold · 3 companies · 1 sharedBenjamin ArnoldPaul Edwards · 3 companies · 1 sharedPaul EdwardsOsteal Therapeutics, Inc. · $127.5M raisedOsteal Therapeutics, …Delta Ortho, LLC · $0.2M raisedDelta Ortho, LLCJude PaganelliJP
Jude Paganelli Company Co-operator (ring = serial)Hover to isolate ties · click to open
Co-operators (shared boards)

People named alongside Jude Paganelli on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.

OperatorSharedTheir companies
David Thompson110
Renee Ryan16
Douglas Kohrs14
Rushu Luo13
Benjamin Arnold13
Paul Edwards13
Biren Mehta12
Martin Sands12
David Cash12
Noam Krantz12
Erik Oros11
Sonal Patel11
Judson Cooper11
Brian De Beaubien11

People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.